Quick Takeaways
- CTKB - Cytek Biosciences, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -18%.
- Info
- Insider Trading
- Financials
- Holders
Cytek Biosciences, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- CTKB on Nasdaq
- Location
- Fremont, CA
- Fiscal year end
- 31 December
- Latest financial report
- 26 Feb 2026
What Changed
- Return On Equity YoY change: <span class="text-green-600">+1082%</span>.
- Most recent SEC facts end date: 17 Feb 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-02-17) highlights Return On Equity -18.0%, Return On Assets -13.8%, and Operating Margin -20.0%.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
34.7/100
Weak Confidence medium
Return On Equity
-18%
Metric score 0.0/100
Return On Assets
-14%
Metric score 0.0/100
Financial Health
- Current Ratio
- 5.04x
- Quick Ratio
- 1.97x
- Debt to Equity
- 0.31x
Strengths
Quick Ratio and Debt-to-equity
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Key metrics snapshot
Return On Equity
-18%
YoY: +1082%
Industry median: -33% (n=32)
Return On Assets
-14%
YoY: +1043%
Industry median: -35% (n=32)
Operating Margin
-20%
YoY: +96%
Industry median: -117% (n=29)
Current Ratio
5.04x
YoY: -14%
Industry median: 2.39x (n=34)
Quick Ratio
1.97x
YoY: -16%
Industry median: 1.68x (n=30)
Debt-to-equity
0.31x
YoY: +19%
Industry median: 0.4x (n=33)
Revenues YoY
0.52%
YoY:
Industry median: 8% (n=20)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -18% | +1082% |
| Return On Assets | -14% | +1043% |
| Operating Margin | -20% | +96% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 5.04x | -14% |
| Quick Ratio | 1.97x | -16% |
| Debt-to-equity | 0.31x | +19% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | 0.52% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 128,550,136 | +1.5% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY